Cytometry · 1999 · 43 citations · 22 references
MedicineHematologyBiocompatibilityHemostasisVascular SurgeryLeukocyte RecruitmentPlatelet ActivationPlatelet AdhesionPlatelet AggregationPlatelet FunctionThrombosisFlow Cytometric Cell AnalysisFlow Cytometric Platelet AnalysisFlow Cytometry ImmunophenotypingLeukocyte AggregationMetallic Stent DesignPlatelet Activation AssaysPlatelet-leukocyte InteractionsStent Biomaterials
Clinical studies suggest that stent design and surface texture are responsible for differences in biocompatibility of metallic endovascular stents. A simple in vitro experimental setup was established to test stent-induced degree of platelet and leukocyte activation and platelet-leukocyte aggregation by flow cytometry. Heparin-coated tantalum stents and gold-coated and uncoated stainless steel stents were tested. Stents were implanted into silicone tubes and exposed to blood from healthy volunteers. Platelet and leukocyte activation and percentage of leukocyte-platelet aggregates were determined in a whole-blood assay by subsequent staining for activation-associated antigens (CD41a, CD42b, CD62p, and fibrinogen binding) and leukocyte antigens (CD14 and CD45) and flow cytometric analysis. Blood taken directly after venous puncture or exposed to the silicone tube alone was used as negative controls. Positive control was in vitro stimulation with thrombin receptor activating peptide (TRAP-6). Low degree of platelet activation and significant increase in monocyte- and neutrophil-platelet aggregation were observed in blood exposed to stents (P < 0.05). In addition, leukocyte activation was induced as measured by increased CD45 and CD14 expression. Heparin coated stents continuously induced less platelet activation and leukocyte-platelet aggregation than uncoated stainless steel stents of the same length and shorter stents of the same structure. Stent surface coating and texture plays a role in platelet and leukocyte activation and leukocyte-platelet aggregation. Using this simple in vitro assay and whole blood and flow cytometry, it seems possible to differentiate stents by their potency to activate platelets and/or leukocytes. This assay could be applied for improving the biocompatibility of coronary stents.
22
Endovascular Stent Design Dictates Experimental Restenosis and Thrombosis
Campbell Rogers, Elazer R. Edelman · Circulation · 1995 · 548 citations
Medicine, Cardiology, Surgery +14
Flow cytometry: a clinical test of platelet function
AD Michelson · Blood · 1996 · 492 citations · Full text
Medicine, Cell Biology, Hematology +16
Heparin-Coated Palmaz-Schatz Stents in Human Coronary Arteries
Patrick W. Serruys, Håkan Emanuelsson, Wim van der Giessen et al. · Circulation · 1996 · 404 citations
Induction of Cytokine Expression in Leukocytes by Binding of Thrombin-Stimulated Platelets
Franz‐Josef Neumann, Nikolaus Marx, Meinrad Gawaz et al. · Circulation · 1997 · 383 citations
Medicine, Cardiology, Immunology +17